Hepatic FNDC5 is a potential local protective factor against Non-Alcoholic Fatty Liver

In conclusion, our human and experimental data strongly suggest that the hepatic expression of FNDC5 increased with hepatic steatosis and its upregulation in hepatocytes could dampen the development of NAFLD by negatively regulating steatogenesis and hepatocyte death.
Source: Biochimica et Biophysica Acta (BBA) Molecular Basis of Disease - Category: Molecular Biology Source Type: research

Related Links:

Publication date: Available online 23 March 2020Source: Pharmacological ResearchAuthor(s): Helda Tutunchi, Alireza Ostadrahimi, Maryam Saghafi-Asl, Mohammad-Javad Hosseinzadeh-Attar, Abolhasan Shakeri, Mohammad Asghari-Jafarabadi, Neda Roshanravan, Nazila Farrin, Mohammad Naemi, Milad Hasankhani
Source: Pharmacological Research - Category: Drugs & Pharmacology Source Type: research
Non-alcoholic fatty liver disease (NAFLD) is considered the hepatic manifestation of the metabolic syndrome, as it is closely related to obesity, dyslipidemia and insulin resistance [1]. Accordingly, the prevalence of NAFLD and non-alcoholic steatohepatitis (NASH), NAFLD ’s later evolutive stage, are increasing at the same pace as obesity becomes a global epidemic. In fact, today, NAFLD is considered to be the number one cause of chronic liver disease worldwide [2-4]. As no specific drugs have yet been approved for NAFLD, at present, the only effective treatment i s weight loss through diet and exercise.
Source: Surgery for Obesity and Related Diseases - Category: Surgery Authors: Tags: Review articles Source Type: research
Non-alcoholic fatty liver disease (NAFLD) is increasing in prevalence in concert with the global epidemic of obesity and is being diagnosed at increasingly younger ages. The unique histological features and early presentation of disease in pediatrics suggest that children and adults may differ in regards to eitopathogenesis, with children displaying a larger vulnerability to genetic and environmental factors. Of significant relevance to pediatrics, in utero and perinatal stressors may alter the lifelong health trajectory of a child, increasing the risk of NAFLD and other cardiometabolic diseases.
Source: Gastroenterology - Category: Gastroenterology Authors: Source Type: research
Source: Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy - Category: Endocrinology Tags: Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy Source Type: research
AbstractBackground and AimIn patients with liver disease, etiology and body mass index (BMI) affects controlled attenuation parameter (CAP) assessment using FibroScan. We aimed to assess the performance characteristics of CAP for hepatic steatosis in patients with non-alcoholic fatty liver disease (NAFLD) stratified into obese (BMI ≥ 30 kg/m2) and non-obese (BMI
Source: Indian Journal of Gastroenterology - Category: Gastroenterology Source Type: research
Authors: Karolczak D, Seget M, Bajerska J, Błaszczyk A, Drzymała-Czyż S, Walkowiak J, Marszałek A Abstract Green tea contains many polyphenolic constitutes, which might prevent non-alcoholic fatty liver disease (NAFLD). We aimed to investigate whether green tea extract (GTE) given at doses reflecting habitual consumption of green tea beverages prevents development of NAFLD in rats fed a high-fat diet (HFD). Twenty-four male Wistar rats were randomly divided into four equal groups (two study and two control groups). The study groups received a HFD (approximately 50% energy from fat), enriched with 1.1% and 2.0% ...
Source: Polish Journal of Pathology - Category: Pathology Tags: Pol J Pathol Source Type: research
AbstractThe growing burden of non-alcoholic fatty liver disease (NAFLD) parallels the increasing prevalence of obesity in Asia. The overall prevalence of NAFLD in Asia is now estimated to be 29.6% and may have surpassed that in Western populations. NAFLD increases with increasing age and is closely associated with metabolic syndrome. Ethnic differences exist in the prevalence of NAFLD, but the underlying factors are unclear. There were initial concerns about lean NAFLD being associated with more severe liver disease and increased mortality, but subsequent studies suggested otherwise. Only some NAFLD patients progress to de...
Source: Indian Journal of Gastroenterology - Category: Gastroenterology Source Type: research
AbstractTherapeutics aimed at treating non-alcoholic fatty liver disease (NAFLD) target the pathogenic process from deranged metabolism leading to steatosis to cell stress and death, leading to a cascade of inflammation and fibrosis, ultimately culminating into cirrhosis. The development of drugs for management of NAFLD has bloomed over the past decade, although at present there is no approved pharmacological agent for its management. Not all patients with the disease progress to cirrhosis and decompensation; hence, treatment specifically is provided for those with a high risk of progression such as those with biopsy-prove...
Source: Indian Journal of Gastroenterology - Category: Gastroenterology Source Type: research
AbstractPurposeBariatric surgery can improve non-alcoholic fatty liver disease (NAFLD). Yet data on the effect on fibrosis are insufficient and controversial. This work endeavored to evaluate the safety of laparoscopic sleeve gastrectomy (LSG) in cases that have compensated non-alcoholic steatohepatitis (NASH)-related cirrhosis and its impact on fibrosis stage.MethodsThe current prospective work involved 132 cases with Child-A NASH-related cirrhosis suffering from morbid obesity scheduled for LSG. They were subjected to preoperative assessment, wedge biopsy, and ultrasound-guided true-cut liver biopsy after 30  months...
Source: Surgical Endoscopy - Category: Surgery Source Type: research
Nature Reviews Gastroenterology &Hepatology, Published online: 09 March 2020; doi:10.1038/s41575-020-0269-9The gut microbiota has been linked to non-alcoholic fatty liver disease (NAFLD), but metabolic confounding factors, such as obesity and diabetes, complicate analysis. This Review provides a broad insight into microbiome signatures for human NAFLD and explores issues with disentangling them from underlying metabolic disorders.
Source: Nature Reviews Gastroenterology and Hepatology - Category: Gastroenterology Authors: Source Type: research
More News: Alcoholism | Carbohydrates | Eating Disorders & Weight Management | Fatty Liver Disease (FLD) | Genetics | Glucosamine | Insulin | Liver | Molecular Biology | Non-alcoholic Fatty Liver Diseases (NAFLD) | Obesity | Sports Medicine | Study | Urology & Nephrology